Due Diligence (9)

Challenge: Alacrita conducted an assessment of an AAV gene therapy for an ophthalmic indication, focusing on market potential, technical and regulatory issues and identification of key risks.

Alzheimer's due diligence Our client, a major pension fund, was considering an investment opportunity in a Phase III neuroscience company. The company was developing a small molecule to provide...

Challenge: A clinical stage biotech needed support with its regulatory due diligence activities for products in the respiratory field.

A life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company. Alacrita was commissioned to provide a reality...

Alacrita's consulting team supports a number of pharmaceutical & biotech companies with medical and clinical strategy. We have particular depth in oncology, but also have expertise in infectious...

Challenge: A major European venture capital investor needed help to review the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a...

Due diligence For a financial investor, Alacrita conducted an IP assessment on a late stage cell therapy investment opportunity. The assessment revealed that the US and EPO patents relied on just...

Alacrita is a leading provider of due diligence to the pharmaceutical industry. Its core team of partners, each of whom has industry experience, are supported by a team of expert, life science...